The Public M&A and Life Sciences team advised Avadel Pharmaceuticals ("Avadel"), a commercial-stage biopharmaceutical company, on a definitive agreement under which Alkermes will acquire Avadel for total transaction consideration of up to $20.00 per share in cash, which values Avadel at approximately $2.1 billion.
The deal marks a significant milestone in the life sciences sector and underscores Goodwin's continued leadership in complex public M&A transactions.
Avadel Pharmaceuticals is a biopharmaceutical company focused on transforming medicines to transform lives. Avadel's approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options.
Alkermes, a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience.
The Goodwin team was led by Rob Puopolo, Blake Liggio, Caitlin Tompkins and Stephanie Isaia.